- Home
- FBYD vs IFRX Comparison
FBYD vs IFRX Comparison
Compare FBYD & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBYD
- IFRX
- Stock Information
- Founded
- FBYD 2021
- IFRX 2007
- Country
- FBYD United States
- IFRX Germany
- Employees
- FBYD N/A
- IFRX N/A
- Industry
- FBYD
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- FBYD
- IFRX Health Care
- Exchange
- FBYD Nasdaq
- IFRX Nasdaq
- Market Cap
- FBYD 120.8M
- IFRX 143.7M
- IPO Year
- FBYD N/A
- IFRX 2017
- Fundamental
- Price
- FBYD $9.19
- IFRX $2.17
- Analyst Decision
- FBYD
- IFRX Strong Buy
- Analyst Count
- FBYD 0
- IFRX 1
- Target Price
- FBYD N/A
- IFRX $8.00
- AVG Volume (30 Days)
- FBYD 29.0K
- IFRX 420.2K
- Earning Date
- FBYD 02-01-2025
- IFRX 11-08-2024
- Dividend Yield
- FBYD N/A
- IFRX N/A
- EPS Growth
- FBYD N/A
- IFRX N/A
- EPS
- FBYD N/A
- IFRX N/A
- Revenue
- FBYD $7,530,000.00
- IFRX $187,930.00
- Revenue This Year
- FBYD N/A
- IFRX $435.15
- Revenue Next Year
- FBYD N/A
- IFRX $180.44
- P/E Ratio
- FBYD N/A
- IFRX N/A
- Revenue Growth
- FBYD N/A
- IFRX 177.12
- 52 Week Low
- FBYD $5.85
- IFRX $1.17
- 52 Week High
- FBYD $13.25
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- FBYD 54.31
- IFRX 51.73
- Support Level
- FBYD $8.51
- IFRX $2.42
- Resistance Level
- FBYD $9.76
- IFRX $2.74
- Average True Range (ATR)
- FBYD 0.92
- IFRX 0.25
- MACD
- FBYD 0.11
- IFRX -0.04
- Stochastic Oscillator
- FBYD 29.26
- IFRX 26.99
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.